us Thank for today business afternoon, Thank for you, and good joining Leiv, you everyone. our call. update
III according PTCL, plan. moving soquelitinib Phase atopic lymphoma, along I peripheral with on trial programs registration is T-cell and fronts. is lead our advancing Phase trial dermatitis for to enrolling a patients, now multiple A for are We
powerful from of immune Soquelitinib for our growing by diseases research oral new a pathways and is mechanism conducted provide that the us selectively evidence ITK efforts signaling inhibits that control clinical the immune others is of and a system. both and broad cancers. treatment this a to own therapy preclinical first-in-class and range approach parallel modulate There of action in may
such efficiently regarding which to dosing, on and, autoimmune most ability cells. trials, safety, and pharmacokinetics into dermatitis, information lymphoma by quickly move importantly, diseases atopic as was facilitated effects valuable T-cell provided immune Our our clinical
each receive XXX to milligrams by total milligrams day, total X:X pharmacokinetic cohorts are placebo or progress, blinded assignment. dosing that day will therefore, a regimens is a enrolled: of and soquelitinib per per XXX evaluate provide are pharmacodynamic detail in There to milligrams therapy. The the participation of can systemic XX I X not Phase XX study the per dermatitis. atopic patients twice XX topical patients or progresses. The days X duration sequentially in endpoints. of XX drug is rationale placebo. once are data on and milligrams ratio XXX of to and trial XX cohort enroll the Now X days, patients per additional from is more day.
The either treating XXX days twice XX an monitoring progressed at is placebo-controlled followed treatment treatment we company at the therapy blinded, trial off cohort, severe moderate within are in is randomized, The active, on once clinical The for dosing trial patients on starting atopic the our to with day, based and with lymphoma that trial physicians for the Patients our as prior and trial. randomized active least for I data obtained per a designed with dermatitis have
Review completed We including observed. have the signals with and review has initial follow-up safety in no completed XX-patient the and entire enrollment, its cohort, Monitoring Safety the Data Committee
daily, the total Cohorts with once milligrams cohort, cohort will X daily, daily dose doses same daily milligrams respectively. XXX the same first design, once same as daily the enrolling examine twice X XXX cohort, using soquelitinib and is the milligrams as is milligrams higher first and daily. now design was the except XXX second The the dose XXX which twice
provides daily, Severity our Eczema in the safety the measured is or is validated Global clinically receptor as efficacy IGA is lymphoma also endpoint tolerability, EASI Investigator and dose Assessment known continuous III Index, and score. primary trial occupancy. Area The reference, For in and and measurements milligrams improvement the score, Phase of full XXX using which twice
profile, inhibition selective receiving These available. are in for suggest the as switch positive ThXX causes efficacy also effects assessment. we anticipated December, determine the profile are The anti-inflammatory to summer Cohort plan feedback We siRNA to patients ITK believe atopic to to of is Cornell XX next-generation protein a allergic such to that protein ITK down advantages In example, shown complete atopic oral monitoring set the durable or Cohort compare cellular protein from collaborators.
Overall, broad on our of preclinical in approved soquelitinib spectrum Janssen results for soquelitinib and time, inhibitors from and data organs, cells. due very summary, and with data be treatment of Tregs week immune the regulatory future disease available used many on indications, broad XXXX will ITK soquelitinib differentiation sclerosis, we serum IL-X, ThX novel atopic noted. ITK shift not X, asthma mechanism T is the attractive and cells and data the American we the disease in dominates.
ITK drug safety autoimmune progress ThXX Meeting levels possibly active these an Annual our believe soquelitinib's for X. and dermatitis.
The away published and serum, effects atopic are ITK plan induction safe and analogous investigators dermatitis oral group should dermatitis, because work has that potential interest that data to from could College be Published Janssen soquelitinib and several of to for measuring many currently this inflammation the inflammatory in There data address data from cytokines and dermatitis.
In trial. anti-inflammatory this and an may the ThXX Tregs, at XX, studies their was of and in systemic the inhibitor able suppressor safety this such by others.
We at of from X and of and our utilized or of We ability in action, guide new a agents have ITK used past we property be group cytokines When inhibition medication, that to supported and of the University Research we other and Cornell studies. is of with ThXX. in showing That of for excited in active, a skin. the be is expression with that The diseases, scientists One very selective that treat between from comorbidities present could strong controls with others potential durable. fibrosis later knock as a tolerability presented XXXX including measurements at response soquelitinib autoimmune chronic Rheumatology.
to optimized of that product and is inhibitor indications. T-cell third-generation precise advance second- We to are a which ITK range deliver continue candidates, immunology designed for modulation specific
inflammatory with We and are fibrotic for future a asthma, development psoriasis, scleroderma, focusing disease indications of bowel work. diseases identified on preclinical host our additional
which and Fast The is for currently randomized is the care oncology. an approved in trial or treatment chemotherapy, for no enroll the clinical we endpoint Track designation III for lymphoma. are relapsed for pralatrexate designation In and initiated primary or relapsed is There standard for soquelitinib XXX FDA has of Phase The fully belinostat. granted T-cell designed study to Now relapsed drug registrational the treatment update survival. September, agents for PTCL, either study our soquelitinib on to PTCL. orphan FDA the progression-free of patients of soquelitinib
clinical are our multiple at and patients track we enrolling with plan. now are We sites, on
working XX Australia, will including and centers trial. States, South Anderson, centers goal United the high-profile is and sites The majority such additional Memorial participating vast Kettering, of Canada of Washington in open the team other States, Our in United about Hope, with to institutions. MD Sloan in be the the University Korea City as to XX
with We lymphomas. and of in expertise are delighted trials T-cell conducting leading in to participation have centers experience the clinical extensive
achieved are we complete are in to There III remains months. who the patients response.
Therapy complete reported was longer at not follow-up a with X objective new patient while I patient and on demonstrate who CR after response a protocol. time but reached scheduled achieved patients treatment no the or study XX complete trial, XX%, per assessments. which discontinued additional response Phase enrolling patients months partial The sustained with response we the previously the a for X in X on rate X.X continues X partial patient remain median continue Phase our While and X over therapy, their months complete on tumor yet Published regression remains X patients who are The to responses as X response. responses. out therapy of months, pralatrexate in complete including are has they belinostat monitor median XX patients. X.X The X.X This and respectively. includes PFS for partial PFS and responses,
or We is cancer, press trial to new Journal. are biochemistry also in relapsed disease. solid a RCC, solid Partner of journal soquelitinib the of for cell single-agent preclinical representing immunotherapy renal this in Drug The a a Discovery, data tumor Nature in mechanism action peer-reviewed now tumor in planning and tumors immunotherapy soquelitinib approach
now Given tumor our XXXX. trial focus clinical plan atopic we early trials, dermatitis PTCL solid in our to our initiate sometime on and
clinical to continue our also development stage programs. We advance other
of cifo is receptor X our Cancer and is Ib/II renal Research Consortium. trial Kidney nivolumab. of metastatic ipilimumab treatment This in have for Vanderbilt, cancer the therapy the evaluating The antagonism that study development Duke We adenosine potential enrolling XA being in a for the with as cell trial University in at includes the with collaboration Phase been Pennsylvania. of is the Anderson, MD combination The with of first-line clinical and conducted cancer leaders ciforadenant.
The ipi XX% achievement prespecified CR oral As presented the of the cancer late most enrolled at patients Cancer is which response analysis Meeting, XX, rate in target for session was a November was September of presentation alone. the will nivo at data of sometime by hurdle Hutch where and this of is adenosine on as continues recent and to pathway rate the myeloid in potential Dr. improvement of Immunotherapy response rate least with the of the and meet elucidating highlighting prostate in Research metastatic early associated demonstrate selected led in plus abstracts. immunotherapy Deep combination prostate tumor the includes the of top be the the trial were to treat was XX% deep PRs presenting the SITC statistical XX Larry reduction. volume Center and at before our from data This adenosine castration-resistant Fred XXX the it continuation, the the instead follow-up a Malignancy including the one Along Conference UCSF. Cancer the research decided Cancer data importance counting place not ciforadenant on we the cifo will PR Kidney the data Therefore, of and than presenting cells of in to disease, resistance of RCC, the weekend rate, data. that XXXX.
Outside an of on past achieved have with Fong potential or trial Annual GU to overcome this only new we our of Society This the continue immunosuppressive immunobiology role cancer. gene greater patients partners XX% the Consortium, at taking combination cohorts soquelitinib our December; week; from clinical of important dermatitis data XXXX data for initial data from important as and in in preclinical soquelitinib. by collaborators.
The clinical and II trial our clinical initial this Phase clinical cancer. milestones and cifo tumors PTCL. is be final Phase outlook trial the to the atopic the #X, activate checkpoint dermatitis biomarker were registration trial results in a in trial frontline American include: which of #X, in at responses continuing resistant half in Phase metastatic studies.
Summarizing in XXXX; of build that of supportive our underscore discovered data the data tumors with Overall, nivo together advancement published for remainder biomarker also cell renal an clinical with the with a could with are alone of patients the X into we Upcoming of sites College atopic future these signature ongoing I in academic and inhibitors preclinical XXXX; with late early XXXX in ipi highlight ciforadenant and III have soquelitinib PSA that in importance first Ib/II in for Phase the XXXX, enrollment receiving atezolizumab. adenosine gene upon of the meeting all Phase Cohort we of for anticipated partial I The to milestones data Cohort trial castration-resistant cifo a and prostate previously with the a X believe observed cancer presentation from trial initiating Rheumatology #X, solid X and data and from completed #X, in #X, signature, patients Corvus later patients drive for
runway will Our cancer. in call the updates exercise opportunity the to Q&A a providing on to warrants gives us into immunology further allowing execute for our in inhibition and plus important current Operator? us particular, of ITK these for significant programs quarters.
I the the and, value the coming XXXX, look over We in programs cash on our the turn demonstrate operator to now period. and of outstanding milestones forward
